CHRS Market Cap History



Below is a table of the CHRS market cap history going back to 11/30/2014:

Date CHRS Market Cap
11/30/2014456.63M
2/28/20151.05B
4/30/2015823.81M
7/31/20151.34B
10/31/20151.08B
1/31/2016518.51M
4/30/2016737.03M
7/31/20161.10B
10/31/20161.19B
2/28/20171.21B
4/28/2017984.73M
7/31/2017672.64M
10/31/2017651.89M
2/28/2018595.40M
4/30/2018740.07M
7/31/20181.29B
10/31/2018795.21M
2/22/20191.02B
4/30/20191.10B
7/31/20191.17B
8/6/201950.63M
10/31/20191.22B
1/31/20201.27B
4/30/20201.18B
7/31/20201.26B
1/31/20211.37B
7/30/2021998.07M
11/5/20211.37B
1/31/2022955.12M
7/31/2022658.33M
10/31/2022676.67M
2/29/2024256.99M
4/30/2024224.86M
7/31/2024177.42M

Also see: CHRS Shares Outstanding History
and CHRS YTD Return
CHRS Historical Market Cap:
-9.31% CAGR
CHRS Historical Market Cap: +-9.31% CAGR

Mouse over chart for data details
11/30/2014 ...7/31/2024
Coherus BioSciences is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Co. in-licensed its lead immuno-oncology product candidate, toripalimab (CHS-007), an anti-PD-1 antibody, from Shanghai Junshi Biosciences Co., Ltd. Toripalimab is being evaluated in late-stage clinical trials for the treatment of a range of tumor types. Co.'s commercial portfolio includes two U.S. Food and Drug Administration-approved biologics, including UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, a granulocyte-colony stimulating factor and YUSIMRY™ (adalimumab-aqvh), its Humira® (adalimumab) biosimilar product. We show 34 historical shares outstanding datapoints in our CHRS shares outstanding history coverage, used to compute CHRS market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing CHRS market cap history over the course of time is important for investors interested in comparing CHRS's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of CHRS versus a peer is one thing; comparing CHRS market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like CHRS can fluctuate over the course of history. With this page we aim to empower investors researching CHRS by allowing them to research the CHRS market cap history.
Quotes delayed 20 minutes

Email EnvelopeFree CHRS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Coherus BioSciences (CHRS) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

CI Market Cap History
CINC Market Cap History
CING Market Cap History
CKPT Market Cap History
CLBS Market Cap History
CLDX Market Cap History
CLNN Market Cap History
CLOV Market Cap History
CLPT Market Cap History
CLRB Market Cap History
More Healthcare companies »

 

CHRS Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.3%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.3%.